BioSpace News Archive

Policy

Phathom Faces Another Delay with H. pylori, Esophagitis Drugs

The FDA issued complete response letters to Phathom Pharmaceuticals, flagging the presence of N-nitroso-vonoprazan (NVP) impurities in its Helicobacter pylori drug products.

February 10, 2023

·

2 min read

·

Tristan Manalac

Employer Resources

Centering Women in Pharma on the Intl. Day of Women and Girls in Science

Feb. 11 is the International Day of Women and Girls in Science. BioSpace spoke with influential women in biotech and biopharma who are working to make a difference in the lives of other women.

February 10, 2023

·

2 min read

·

Hayley Shasteen

Business

Eliem Cuts MDD Candidate, 55% of Staff in Kv7 Program Pivot

Eliem Therapeutics is dropping a depression drug candidate and laying off 55% of staff in an attempt to stretch its cash runway to 2027.

February 10, 2023

·

1 min read

·

Rosemary Scott

Pictured: Financing concept/Getty Images

IPO Doors Creak Open as Mineralys Seeks $192M

Mineralys Therapeutics hopes to raise $192 million in its initial public offering - one week after Structure Therapeutics announced its own IPO.

February 10, 2023

·

2 min read

·

Tristan Manalac

Pharm Country

Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners

Neuronetics, Inc. announced a healthcare policy update from National Government Services, Inc. that increases access for patients to its NeuroStar® Advanced Therapy for Mental Health transcranial magnetic stimulation.

February 10, 2023

·

3 min read

Business

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products reported business and financial results for the fiscal first quarter ended December 31, 2022.

February 10, 2023

·

11 min read

BioMidwest

ZIVO Bioscience Announces Results of Study with its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Zivo Bioscience, Inc. announced the results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial in broiler chickens.

February 10, 2023

·

4 min read

DBV Technologies to Participate in Upcoming Investor Conference - February 10, 2023

DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the virtual SBV Securities Global Biopharma Conference taking place February 13 – 16, 2023.

February 10, 2023

·

1 min read

Business

Integrated BioPharma Reports Results for its Quarter Ended December 31, 2022

Integrated BioPharma, Inc. reports its financial results for the quarter ended December 31, 2022.

February 10, 2023

·

5 min read

Genetown

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

CureVac N.V. announced the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by CureVac.

February 10, 2023

·

5 min read